Long-acting growth hormone shows transient BMI increase in children, raising treatment compliance concerns

The transient increase in BMI associated with long-acting growth hormone treatments raises concerns about patient compliance and long-term safety. This could influence prescribing practices and necessitate closer monitoring of real-world data to ensure effective treatment strategies.

The transient increase in BMI associated with long-acting growth hormone treatments raises concerns about patient compliance and long-term safety. This could influence prescribing practices and necessitate closer monitoring of real-world data to ensure effective treatment strategies.

Trial Update

Long-acting growth hormone treatments like Somapacitan and Somatrogon show a transient increase in BMI during the first year of treatment in children, with some patients experiencing significant weight gain.

The transient increase in BMI associated with long-acting growth hormone treatments raises concerns about patient compliance and long-term safety. This could influence prescribing practices and necessitate closer monitoring of real-world data to ensure effective treatment strategies.

Upcoming real-life data presentations and publications on long-term BMI changes in children treated with long-acting growth hormone.